Introduction

!
Platycodon grandiflorum, the dried root of Platycodon grandiflorum A. DC (Campanulaceae), Platycodi Radix, has been commonly used as food and herbal medicine for the treatment of cough, cold, sore throat, tonsillitis, bronchitis, bronchial asthma, and chest congestion [1] . A lot of Chinese medicine preparations with Platycodon grandiflorum as a main crude drug are widely used in the current clinic. Triterpenoid saponins are the major active components of this plant, and more than 30 saponins have been reported [2] [3] [4] [5] [6] [7] [8] [9] . These saponins of Platycodon grandiflorum are believed to contribute, along with other components, to the therapeutic efficacy of this medicinal plant considering its multiple functions: anti-inflammatory [10, 11] , hypoglycemic, and anticancerogenic effects [12] [13] [14] , among others. Among these saponins, PD is one of the important chemical components in Platycodon grandiflorum in terms of the quantity and serves as an index to monitor the quality of any process including this plant in the industry. There are two unbranched sugar chains attached to the carbons C-3 and C-28 in the aglycones in PD, and each chain is composed of one (C-3) and four monosaccharide (C-28) residues. Pharmacological studies have reported that PD possesses many biological activities such as anti-inflammatory [15, 16] , hyperlipidemic [17, 18] , and antiallergic properties [10] , as well as protective effects on oxidative hepatotoxicity [19] , stimulating apoptosis in cancer cells and exerting anticancer activities [5, [20] [21] [22] . However, the research on pharmacokinetics of PD lags behind compared to its pharmacological studies. To the best of our knowledge, there is no report to characterize the pharmacokinetic property of PD in any species of animal yet, which raises the necessity to conduct pharmacokinetic studies to understand the in vivo PK properties of PD and eventually explore the mechanisms of its pharmacological effects.
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Platycodin D (PD), a major component isolated from the root of Platycodon grandiflorum, is widely used in traditional Chinese medicine. A sensitive rapid analytical method was established and validated to determine the PD in rat plasma. This method was further applied to assess the pharmacokinetics of PD in rats following administration of a single dose. Liquid chromatography tandem mass spectrometry (LC/MS/MS) in multiple reaction monitoring mode (MRM) was used in the method, and tubeimoside I was used as the internal standard (IS). A simple protein precipitation based on methanol (MeOH) was employed. The combination of a simple sample cleanup and short chromatographic running time (4 min) increased the throughput of the method substantially. The method was validated over the range of 0.5-1000 ng/mL with a correlation coefficient > 0.99. The lower limit of quantification was 0.5 ng/mL for PD in plasma. Intra-and inter-day accuracies for PD were 90-115 % and 96-108 %, respectively, and the inter-day precision was less than 15 %. After a single oral dose of 10 mg/kg of PD, its mean peak plasma concentration (C max ) was 13.7 ± 4.5 ng/mL at 0.5 h. The area under the plasma concentration-time curve (AUC 0-24 h ) was 35.4 ± 16.1 h·ng/mL, and the elimination half-life (T 1/2 ) was 1.48 ± 0.13 h. In case of intravenous administration of PD at a dosage of 0.5 mg/kg, the area under the plasma concentration-time curve (AUC 0-24 h ) was 2203 ± 258 h · ng/mL, and the elimination half-life (T 1/2 ) was 6.57 ± 0.70 h. Based on the results, the oral bioavailability of PD in rats at 10 mg/kg is 0.079 %.
To initiate the pharmacokinetic evaluation of the compound of interest, a prerequisite is to establish a sensitive, accurate, and reliable quantification method to determine the concentration of the compound in the intended biological samples. Liquid chromatography tandem mass spectrometry (LC/MS/MS) is currently the best method of choice for a pharmacokinetic study due to its high sensitivity and specificity. However, there is no LC/MS/MS method published yet to measure the level of PD in any biological matrix. In the present study, we developed and validated a sensitive and robust LC/MS/MS method for the determination of PD in rat plasma. Our method included the simple and straightforward protein precipitation procedure for sample cleanup and a short chromatographic run by LC/MS/MS (4 min) allowing a highthroughput analysis for the pharmacokinetic study. Thereafter, the developed method was applied to measure the concentration of PD in rat plasma and look into the pharmacokinetic behavior of PD in rats after a single administration.
Materials and Methods
!
Materials and reagents
Reference standard of PD (> 98 %) was provided by Shanghai Hyperheal Science and Technology Co., Ltd., and the reference standard of tubeimoside I (IS, > 98%) was purchased from the National Institute for the Control of Pharmaceutical and Biological Products and used as the internal standard for quantification of PD. HPLC-grade methanol (MeOH) and formic acid were obtained from Fisher. Distilled water was produced with a Millipore water purification system. The primary stock solution of PD was prepared in 50 %-MeOH at 1.0 mg/mL. The stock solution was serially diluted to the spiking solutions with concentrations of 10 000, 5000, 1000, 500, 100, 20, 10, and 5 ng/mL, respectively, which were used for the plotting of standard curves. Primary IS stock solution and intermediate IS stock solution were prepared by using 50 %-MeOH in water as the solvent and for the dilution, respectively. The IS spiking solution (2 µg/mL) was prepared from the intermediate IS stock solution using water for dilution. Stock solutions of both PD and IS were stored at − 80°C when not in use.
Animal study
Male Sprague Dawley rats with a body weight of~250 g were purchased from Sino-British Sippr/BK Lab Animal Ltd. (quality certificate No.: 2008001609322). The rats were maintained in an air-conditioned animal quarter with alternating 12-h light/ dark cycles at a room temperature of 22 ± 2°C and a relative humidity of 50 ± 10 %. The rodents were given a commercial rat chow and water ad libitum. Rat studies were conducted according to protocols approved by the Review Committee of Animal Care and Use at Longhua Hospital (Shanghai, China; approval No.: A20110301; date of approval: March 1, 2011). The experiment started after acclimation to the facilities for 3 days. The animals were fasted overnight (~12 h) and had free access to water throughout the experimental period. Platycodon grandiflorum is used orally in clinics, and the typical dosage is 30-60 g per person (60 kg of body weight) with the median value at 0.75 g/kg. In the present study, the dosage in a rat was reasonably calculated by converting the human dosage with the conversion rate at 1 : 6 (human to rat) [23] . It has been reported that the content of PD in Platycodon grandiflorum is 2.13 mg/g [24] ; thus, the oral dosage in a rat PK study of PD was designed to be 10 mg/kg so as to mimic the case in the clinic. Ideally, the dosage for intravenous administration of PD should be set at 10 mg/kg as well as for accurate comparison of pharmacokinetic parameters. However, it is also noted that saponin can cause the lysis of red blood cells [25] . To minimize this side effect to the animal, the dosage should be as low as possible, which, however, could challenge the sensitivity of the analytical method for quantification. Eventually, the dosage used was 0.5 mg/kg to balance these two factors. Ten male SD rats were divided into two groups randomly: one group was given a single dose of 10 mg/kg PD orally, and the other group 0.5 mg/kg PD intravenously. The blood samples (~200 µL) were taken via the jugular vein catheter from non-restrained non-sedated animals into tubes pretreated with heparin before dosing and subsequently at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 24 h after oral dosing and at 0.083, 0.167, 0.33, 0.5, 1, 2, 3, 4, 6, 8, 24 h after intravenous dosing. The blood samples were centrifuged at 4000 g for 10 min at 4°C to give duplicates of 50 µL plasma samples. These samples were stored at − 80°C immediately until analysis.
Plasma sample preparation
The thawed plasma samples (50 µL) were mixed with 5 µL of the IS spiking solution (tubeimoside I, 2 µg/mL). 150 µL MeOH was then added for protein precipitation. After vortexing for 2 minutes and centrifuging for 5 minutes at 13 000 g at 4°C, 150 µL aliquots of supernatant were transferred to autosampler vials for LC/MS/MS analysis.
Liquid chromatography/tandem mass spectrometry
The liquid chromatography/tandem mass spectrometry (LC/MS/ MS) system consisted of an Agilent high-performance liquid chromatograph (HPLC) 1200 series system (including a vacuum degasser, a binary pump, and a column oven) and a CTC autosampler coupled to an API 4000 triple-quadrupole mass spectrometer equipped with a TurboIonSpray ion source. The LC/MS/MS system was controlled by Analyst 1.4.2 software, which also acquired and processed the data. LC separation was performed on a 5 µm Agel Luna C18 (50 × 2.1 mm, i. d.) at room temperature with a 2-µm filter used before the analytical column. The LC mobile phase was H 2 O containing 0.1 % formic acid (A) and MeOH (B) at a flow rate of 0.30 mL/min. A gradient elution program was used as follows: 0 → 2.5 min, B% 60 → 90; 2.5 → 2.6 min, B% 90 → 60; 2.6 → 4 min, B% 60 → 60. The injection volume was 10 µL, and the temperature of the autosampler was set at 4°C to keep the samples stable during the analysis. The operating parameters of the ion source were optimized using 10 µg/mL tuning solution of PD to obtain the best performance from the mass spectrometer for the analysis of PD. Prior to being introduced into the MS detector, the tuning solution, delivered at 5.0 µL/min by a syringe pump, was combined through a PEEK Tconnector with mobile phase, delivered at 0.3 mL/min by an HPLC pump. The sensitivity of detection of both PD and IS in the negative ion mode was found to be higher than that in the positive mode. Therefore, instrumental parameters were tuned to maximize the generation of the deprotonated molecule,
, of PD and to efficiently produce characteristic fragment ions. Typical sets of parameters used in this study were as follows: the source parameters, including curtain gas, gas 1, gas 2, collision gas (CAD), capillary temperature (TEM), and ion spray voltage, were set at 15 psi, 50 psi, 40 psi, 10 psi, 550°C, and − 4.5 kV, respectively; the compound parameters, including declustering potential (DP), entrance potential (EP), collision energy (CE), and collision cell exit potential (CXP), were − 230 V, -12 V, -80 V, and − 27 V for PD, and − 170 V, -6 V,-52 V, and − 15 V for the internal standard (IS), respectively. The MS detector was operated in multiple reaction monitoring (MRM) mode at unit mass resolution for quantification of PD in plasma samples with the dwell time at 100 ms. The precursor-to-product ion transition for PD was m/z 1223.6 → 469.0 and m/z 1317.8 → 1233.9 for IS.
Calibration curves
Calibration curves were prepared by spiking 5 µL of spiking solution into 45 µL of blank plasma to produce the standard samples at concentrations of 1000, 500, 100, 50, 10, 2, 1, and 0.5 ng/mL, respectively. Each sample contained 200 ng/mL of IS. Zero plasma samples used in each run were prepared containing 200 ng/mL of IS only. The plasma samples for calibration were precipitated with MeOH and prepared under the same conditions as the test samples. In each run, a plasma blank, a zero standard (with IS only), and a set of calibration standards were analyzed where the lower limit of quantification (LLOQ) and upper limit of quantification (ULOQ) were used in duplicate.
Validation
The assay here was validated according to the U. S. FDA guidance on bioanalytical method validation. Selectivity and specificity of the assay were assessed by analyzing six different lots of rat blank plasma to see if there was chromatographic interference at retention times of PD and IS from endogenous plasma components. Stability of PD was evaluated at 800 and 2 ng/mL in triplicates under conditions mimicking situations likely to be encountered during the sample storage, preparation, and the analytical process, including − 80°C storage in stock solution for 7 days, 23°C storage in rat plasma for 8 h, three cycles of freeze/thaw (− 80 ↔ 23°C), and autosampler storage in the reconstitution solution for 12 h. Samples were considered to be stable if assay values were within the acceptable limits of accuracy (± 15 % DEV) and precision (± 15% CV). To determine the accuracy and precision, the method developed here was validated by analyzing quality control (QC) samples 3 times, which were prepared by spiking known amounts of PD in blank plasma at low (2 ng/mL, LQC), medium (50 ng/mL, MQC), and high concentrations (800 ng/mL, HQC). The measured value was calculated from the calibration curve obtained in the same run, expressed as the mean of the 3 values. The accuracy was measured as the difference between the nominal value and measured value expressed as a percentage of the nominal value. The precision was expressed as the coefficient of variation (CV), i.e., the standard deviation divided by the mean value multiplied by 100. The recovery of PD and IS was determined by comparing the peak area of the precipitated plasma samples at three QC concentrations in triplicate to the peak area of neat standard in post-precipitated samples. The matrix effect was determined at the same three concentrations by comparing peak areas of neat standard in post-precipitated samples (from six batches of rat plasma) with those of other neat solution (water) standards. Recoveries and matrix effects were determined at 2, 50, and 800 ng/mL, whereas the recovery of IS was determined at the concentration of 200 ng/ mL, which was used throughout the analysis.
Pharmacokinetic analysis
The plasma concentration-time data for PD in rats were analyzed by the WinNonlin 5.2.1 software (Pharsight), employing the noncompartmental model. The peak plasma concentration (C max ) and the corresponding time (T max ) after oral administration were directly obtained from the concentration data.
Results and Discussion
!
To develop a sensitive MS/MS method for detection of PD in biological samples, a comparison between the ionization of PD in the negative and positive ion modes was performed on a TurboIonSpray ion source in terms of the intensity of ions produced. Our research results showed that the intensity of the most abundant molecule ion for PD produced in the negative ion mode was much stronger than that in the positive mode (data not shown), due to the existence of hydroxyl and carboxyl groups. Under the same MS detector conditions, tubeimoside I, the internal standard due to its similarity in chemical structure to PD, could be ionized efficiently as well. Thus, the TurboIonSpray ion source was operated in the negative ion mode for analysis of PD throughout this study. The most intense peaks in the MS spectra of PD and IS were the ions at m/z 1223.6 and 1317.8, corresponding to the deprotonated molecules [M -H] − . The stable fragment ions for PD and IS were found at m/z 469.0 and 1233.9, respectively, and were produced by the cleavage of the bond indicated in l " Fig. 1 . These product ions were used for quantification of PD in rat plasma. After the optimization of the gradient program for LC separation, the chromatographic retention time of PD and IS were at 1.8 and 2.9 min with a good peak shape and symmetry, and the total running time for one sample was 4 min, which rendered the method high-throughput and suitable for routine plasma analysis in a pharmacokinetic study. Our stability experiment showed that PD was stable up to 8 h in rat plasma, up to 12 h in reconstitution solvent, up to 7 days in stock solution and could withstand 3 cycles of the freeze-thaw process (l " Table 1), which illustrated that PD would not degrade during the process of sample storage, preparation, and analysis. LC/MS/MS chromatograms of six lots of control blank rat plasmas did not show coelution of endogenous compounds at the retention times of both PD and IS. The chromatograms of the zero standard sample showed that IS used in this study would not interfere in the detection of PD by MS (l " Fig. 2 B) . The short retention times of PD (1.8 min) and IS (2.9 min) made it necessary to evaluate the matrix effects of biosamples on analyte ionization under the optimized assay conditions at three concentrations (2, 50, and 800 ng/mL). As shown in l " Table 2 , the results indicated that endogenous components retained in the plasma could interfere in the MS detection of PD with a matrix effect at 62-76 %. But the extension was in the range of practical acceptance (50-150 %) and consistent among different concentrations (2 to 800 ng/mL) with CV < 10 %. Thus, no further optimization for LC separation and the sample cleanup procedure was continued here. Under these conditions, the matrix effect of IS was in the range of 97-119% indicating interference found on the detection of IS. The recovery efficiencies of the MeOH-based protein precipitation procedure for PD at three different concentrations (2, 50 , and 800 ng/mL) were 71-84 % and that for IS at 200 ng/mL was 87-115%, and the recoveries of both PD and IS were consis-tent, precise, and reproducible, which proved the suitability of the procedure for sample cleanup (l " Table 3 ). The plasma calibration curve was constructed using eight calibrators ranging from 0.5 to 1000 ng/mL. The standard curve had a reliable reproducibility over the standard concentrations across the calibration range. The calibration curve was prepared by determining the best fit of peak area ratios of analyte to IS (Y) versus concentrations (X, ng/mL), and a typical regression equation for PD was Y = 0.082X + 0.00 688 with a weighting factor of 1/X 2 . The average correlation coefficient was > 0.99. The lowest concentration with the CV < 20 % was taken as the LLOQ and was found to be 0.5 ng/mL. The precision of this analytical method was investigated by calculating the relative standard deviation (RSD) of the concentrations on the same day (n = 3) and on different days (n = 5) for QC samples, which were blank plasma samples spiked with different amounts of PD (2, 50, and 800 ng/mL). As shown in l " Table 4 , the precision for either intraday or inter-day never exceeded 15 % at any of the concentrations, indicating good assay precision. Meanwhile, the accuracy ranged from 90 to 115 %. The LC/MS/MS method for the determination of the concentration in rat plasma has been developed and validated successfully for the first time. The method was further applied to analyze the plasma samples of rats treated with PD. l " Fig. 3 illustrates the concentration versus time profiles of PD with a single intravenous and oral dose administered to five individual rats for each group. Based on the concentration data, the pharmacokinetic parameters have been calculated by WinNonlin using the non-compartmental analysis (l " Table 5 ). The mean peak concentration (C max ) was achieved at 0.5 h with the relatively low value of 13.7 ± 4.5 ng/mL after oral administration of 10 mg/kg PD. PD in oral group rats plasma was detectable up to 6 h (1.02 ± 0.50 ng/ mL), and after 6 h, the level of PD in all rat plasma declined to less than 0.5 ng/mL. The systemic exposure to PD was very poor as indicated by the low AUC 0-24 h (35.4 ± 16.1 h · ng/mL). For intravenous administration of PD, the dosage was set at 0.5 mg/kg to avoid the lysis of red blood cells caused by saponins. In our PK in-life experiment, no obvious lysis occurred at this dose level in the rats. The AUC 0-24 h was 2203 ± 258 h · ng/mL after intravenous administration. The linear logarithm has been found in the elimination phase of the pharmacokinetic curve, and the T 1/2 of this compound was 6.57 ± 0.70 h. The oral bioavailability calculated by (AUC po /dose)/(AUC iv /dose) of PD in rats was very low, about 0.079 %. The poor systemic exposure to PD is similar to the one to saponins from other herbs. Ginsenosides were found to have low systemic exposure in rats after oral administration of Panax notoginseng extract, in which ginsenosides are the major compo- Fig. 2 A to C LC/MS/MS chromatograms of (A) blank rat plasma sample; B blank rat plasma sample spiked with standard PD and IS; C rat plasma sample collected after a single dose of PD. nents responsible for its therapeutic effects [26] . The reason underlying this phenomenon could be: a) the degradation of saponin in the gastric-intestinal tract: the sugar moieties are unstable in the acidic environment (the pH of gastric acid is about 1.2) and degradable by the intestinal bacteria, which can cause the deglycosylation of the parent saponin; b) poor membrane permeability: saponins have been reported to have limited intestinal absorption because the sugar moieties increase the hydrogen bond count, polar surface area, and molecular flexibility of the molecules to unfavorable levels [27] ; c) rapid elimination: most saponins were subject to rapid extensive biliary excretion through active transport, resulting in their short T 1/2 values and low systemic exposure levels. However, in this specific case, the T 1/2 of PD in intravenous administration rats was 6.57 ± 0.70 h and, relatively, long enough to maintain the concentration of PD in the circulating system. Thus, we can deduce that the low bioavailability of PD could result from the degradation in the GI tract and its poor membrane permeability so as to limit the intestinal absorption. Further experiments will be conducted to confirm this deduction. All data presented here indicate that the established method in this study was able to be used in the pharmacokinetic study of PD in the form of either the pure chemical or a Chinese herbal extract containing PD. Other saponins in Platycodon grandiflorum have also been reported to demonstrate pharmacological activities, such as eliciting Th1 and Th2 immune responses of platycodin D2 [28] , improving specific cellular and humoral responses to hepatitis B surface antigen of platycodin D2 [29] , and anti-inflammatory activity of the prosapogenin methyl ester of platycodin D [30] . Those saponins have similar chemical structures to PD, which in- Table 2 Matrix effect of PD and IS by the current method (n = 6).
Compound Matrix 2 ng/mL 50 ng/mL 800 ng/mL Peak area ME (%) Peak area ME (%) Peak area ME (%) dicates that the method we developed here can serve as the basis for the development of other methods using LC/MS/MS to understand the in vivo pharmacokinetic properties of those compounds. The LC/MS/MS-based method described in this study can determine the concentration of PD in rat plasma with tubeimoside I as internal standard. The simple sample cleanup procedure and short chromatographic running time increased the throughput of sample analysis. To the best of our knowledge, the present method offers the highest sensitivity (0.5 ng/mL) and shortest running time (4 min). The method was further applied to study the pharmacokinetics of PD after a single administration in rats successfully for the first time, which indicates that our method is able and sufficient to be used in the drug metabolism and pharmacokinetic study of PD and other Chinese medicinal preparations containing PD. 
